133 related articles for article (PubMed ID: 23504603)
1. Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer.
Shao N; Wang Y; Jiang WY; Qiao D; Zhang SG; Wu Y; Zhang XX; Wang JL; Ding Y; Feng NH
Int J Cancer; 2013 Oct; 133(7):1743-50. PubMed ID: 23504603
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of zibotentan in the treatment of castration-resistant prostate cancer: a meta-analysis.
Wu Y; Shao N; Shen ZX; Li Q; Wang Y; Li C; Ma G; Dong J; Lu XJ; Feng NH
Eur Rev Med Pharmacol Sci; 2014; 18(21):3291-6. PubMed ID: 25487941
[TBL] [Abstract][Full Text] [Related]
3. A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.
Qi P; Chen M; Zhang LX; Song RX; He ZH; Wang ZP
PLoS One; 2015; 10(7):e0133803. PubMed ID: 26192308
[TBL] [Abstract][Full Text] [Related]
4. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.
Nelson JB; Fizazi K; Miller K; Higano C; Moul JW; Akaza H; Morris T; McIntosh S; Pemberton K; Gleave M
Cancer; 2012 Nov; 118(22):5709-18. PubMed ID: 22786751
[TBL] [Abstract][Full Text] [Related]
5. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
Miller K; Moul JW; Gleave M; Fizazi K; Nelson JB; Morris T; Nathan FE; McIntosh S; Pemberton K; Higano CS
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):187-92. PubMed ID: 23381694
[TBL] [Abstract][Full Text] [Related]
6. ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer.
Warren R; Liu G
Expert Opin Investig Drugs; 2008 Aug; 17(8):1237-45. PubMed ID: 18616419
[TBL] [Abstract][Full Text] [Related]
7. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
Fizazi K; Higano CS; Nelson JB; Gleave M; Miller K; Morris T; Nathan FE; McIntosh S; Pemberton K; Moul JW
J Clin Oncol; 2013 May; 31(14):1740-7. PubMed ID: 23569308
[TBL] [Abstract][Full Text] [Related]
8. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
James ND; Caty A; Payne H; Borre M; Zonnenberg BA; Beuzeboc P; McIntosh S; Morris T; Phung D; Dawson NA
BJU Int; 2010 Oct; 106(7):966-73. PubMed ID: 20840318
[TBL] [Abstract][Full Text] [Related]
9. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
10. Current and emerging treatments in the management of castration-resistant prostate cancer.
Shapiro D; Tareen B
Expert Rev Anticancer Ther; 2012 Jul; 12(7):951-64. PubMed ID: 22845410
[TBL] [Abstract][Full Text] [Related]
11. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
12. Novel options for the treatment of castration-resistant prostate cancer.
Ohlmann CH; Merseburger AS; Suttmann H; Schilling D; Trojan L; Kempkensteffen C; Corvin S; Mathers MJ; Bastian PJ
World J Urol; 2012 Aug; 30(4):495-503. PubMed ID: 22101903
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.
Heidegger I; Massoner P; Eder IE; Pircher A; Pichler R; Aigner F; Bektic J; Horninger W; Klocker H
J Steroid Biochem Mol Biol; 2013 Nov; 138():248-56. PubMed ID: 23792785
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis.
Botrel TE; Clark O; Pompeo AC; Bretas FF; Sadi MV; Ferreira U; Reis RB
Int Braz J Urol; 2012; 38(6):717-27. PubMed ID: 23302410
[TBL] [Abstract][Full Text] [Related]
15. [New drugs in metastatic castration-resistant prostate cancer].
Albiges L; Loriot Y; Gross-Goupil M; de La Motte Rouge T; Blesius A; Escudier B; Massard C; Fizazi K
Bull Cancer; 2010 Jan; 97(1):149-59. PubMed ID: 20022854
[TBL] [Abstract][Full Text] [Related]
16. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
Di Lorenzo G; Ferro M; Buonerba C
BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
[TBL] [Abstract][Full Text] [Related]
17. Castration-resistant prostate cancer: AUA Guideline.
Cookson MS; Roth BJ; Dahm P; Engstrom C; Freedland SJ; Hussain M; Lin DW; Lowrance WT; Murad MH; Oh WK; Penson DF; Kibel AS
J Urol; 2013 Aug; 190(2):429-38. PubMed ID: 23665272
[TBL] [Abstract][Full Text] [Related]
18. [Immunotherapy: an emerging strategies against prostate castration resistant cancer].
Mansi L; Thiery-Vuillemin A; Kalbacher E; Nguyen T; Maurina T; Nallet J; Kim S; Borg C; Kleinclauss F; Pivot X; Adotevi O
Bull Cancer; 2012 Jul; 99 Suppl 1():S57-65. PubMed ID: 22516539
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
20. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens.
Caubet JF; Tosteson TD; Dong EW; Naylon EM; Whiting GW; Ernstoff MS; Ross SD
Urology; 1997 Jan; 49(1):71-8. PubMed ID: 9000189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]